Your browser doesn't support javascript.
loading
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
Amaria, Rodabe N; Prieto, Peter A; Tetzlaff, Michael T; Reuben, Alexandre; Andrews, Miles C; Ross, Merrick I; Glitza, Isabella C; Cormier, Janice; Hwu, Wen-Jen; Tawbi, Hussein A; Patel, Sapna P; Lee, Jeffrey E; Gershenwald, Jeffrey E; Spencer, Christine N; Gopalakrishnan, Vancheswaran; Bassett, Roland; Simpson, Lauren; Mouton, Rosalind; Hudgens, Courtney W; Zhao, Li; Zhu, Haifeng; Cooper, Zachary A; Wani, Khalida; Lazar, Alexander; Hwu, Patrick; Diab, Adi; Wong, Michael K; McQuade, Jennifer L; Royal, Richard; Lucci, Anthony; Burton, Elizabeth M; Reddy, Sangeetha; Sharma, Padmanee; Allison, James; Futreal, Phillip A; Woodman, Scott E; Davies, Michael A; Wargo, Jennifer A.
Afiliação
  • Amaria RN; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Prieto PA; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Tetzlaff MT; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Reuben A; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Andrews MC; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ross MI; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Glitza IC; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Cormier J; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hwu WJ; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Tawbi HA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Patel SP; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lee JE; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Gershenwald JE; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Spencer CN; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Gopalakrishnan V; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Bassett R; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Simpson L; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Mouton R; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hudgens CW; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zhao L; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zhu H; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Cooper ZA; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wani K; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lazar A; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hwu P; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Diab A; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wong MK; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • McQuade JL; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Royal R; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lucci A; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Burton EM; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Reddy S; Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Sharma P; Department of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Allison J; Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Futreal PA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Woodman SE; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Davies MA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wargo JA; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: jwargo@mdanderson.org.
Lancet Oncol ; 19(2): 181-193, 2018 02.
Article em En | MEDLINE | ID: mdl-29361468
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oximas / Piridonas / Pirimidinonas / Neoplasias Cutâneas / Imidazóis / Melanoma Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Humans / Middle aged País/Região como assunto: America do norte Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oximas / Piridonas / Pirimidinonas / Neoplasias Cutâneas / Imidazóis / Melanoma Tipo de estudo: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Humans / Middle aged País/Região como assunto: America do norte Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Reino Unido